Amgen
FDA Approves Amgen's Lumakras for NSCLC Alongside Companion Tests From Guardant Health, Qiagen
The approval makes Lumakras the first inhibitor of KRAS, once considered "undruggable," to reach the market for KRAS-mutated NSCLC.
Amgen, NeoGenomics Partner to Expand Biomarker Testing Access in NSCLC
As part of its Biomarker Assist program, Amgen will cover the cost of NeoGenomics' KRAS tests for advanced or metastatic NSCLC patients regardless of their insurance status.
Grail Inks Deals With Amgen, AstraZeneca, Bristol Myers Squibb for MRD Test Development
The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.
Anti-SARS-CoV-2 Antibodies Do Not Decline Within Four Months, New Study Finds
DeCode Genetics researchers found patients' antibody titers increased in the two months following diagnosis, then stabilized.
Adaptive Eyes NGS-Based Test for T Cell Response in COVID-19
The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.
Jan 11, 2017